Westfield Capital Management Co. LP Acquires 544 Shares of Eli Lilly and Company $LLY

Westfield Capital Management Co. LP grew its holdings in Eli Lilly and Company (NYSE:LLY) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 277,549 shares of the company’s stock after purchasing an additional 544 shares during the period. Eli Lilly and Company comprises about 1.2% of Westfield Capital Management Co. LP’s investment portfolio, making the stock its 14th biggest holding. Westfield Capital Management Co. LP’s holdings in Eli Lilly and Company were worth $298,277,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Cidel Asset Management Inc. increased its holdings in shares of Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares in the last quarter. Spire Wealth Management increased its holdings in shares of Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares in the last quarter. Coldstream Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after purchasing an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after purchasing an additional 7,338 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in shares of Eli Lilly and Company by 3.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after purchasing an additional 5,595 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Health’s latest move is being seen as another win for Eli Lilly’s LillyDirect ecosystem, strengthening its position in the chronic weight-management market and potentially expanding access to patients using Lilly’s obesity treatments. Article Title
• Positive Sentiment: WW International said its WeightWatchers Med+ program is now available through LillyDirect, which could help broaden the reach of GLP-1-based weight-loss care and reinforce demand around Eli Lilly’s obesity franchise. Article Title
• Positive Sentiment: Eli Lilly’s $1.9 billion partnership with Ascidian Therapeutics adds another growth avenue outside obesity, signaling continued investment in genetic medicine and kidney-disease therapies that could diversify future revenue. Article Title
• Positive Sentiment: Multiple commentary pieces highlighted Lilly as a buy and noted continued strength in its obesity, gene-editing, vaccine, and cancer pipelines, which may be supporting investor sentiment. Article Title
• Neutral Sentiment: Several market-watchlist and “stock of the day” articles kept Eli Lilly in the spotlight, but they did not add material new fundamentals beyond broader bullish coverage. Article Title
• Negative Sentiment: The Ascidian deal was also reported alongside a stock dip in one headline, suggesting some investors may be cautious about the size of Lilly’s acquisition and partnership spending even as they like the strategic logic. Article Title

Analyst Upgrades and Downgrades

Several brokerages recently commented on LLY. Scotiabank reaffirmed an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Daiwa Securities Group lifted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,125.00 on Friday. The company has a market capitalization of $1.06 trillion, a PE ratio of 39.96, a price-to-earnings-growth ratio of 1.18 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business’s fifty day moving average is $970.24 and its 200 day moving average is $1,012.19. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,149.10.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.